<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Evaluation of the Patient with Asymptomatic Microscopic Hematuria" /><meta property="og:locale" content="en" /><meta name="description" content="Asymptomatic microscopic hematuria (AMH) is relatively common in clinical practice but the etiology remains unclear in the majority of patients; it is rarely related to genitourinary malignancies. The 2012 guidelines of the American Urological Association recommend an evaluation after a single positive urinalysis with mandatory upper tract evaluation in all patients, preferably with CT urography (CTU). The likelihood of detecting significant upper track abnormalities, particularly malignancies is low with CTU, while incidental extraurinary abnormalities are often found, the majority of which are not clinically significant. The workup for these incidental findings has significant financial and clinical implications. Primary care physicians, who are most apt to encounter patients with AMH, have a low rate of adherence to the AUA guidelines, possibly as a result of the broadening of criteria for AMH evaluation by the AUA, with resultant uncertainty amongst primary care physicians about the appropriate candidates for such evaluation. Selection of subgroups of patients with risk factors for GU malignancies who may benefit from a complete evaluation is essential, as opposed to evaluation of all patients classified as having AMH." /><meta property="og:description" content="Asymptomatic microscopic hematuria (AMH) is relatively common in clinical practice but the etiology remains unclear in the majority of patients; it is rarely related to genitourinary malignancies. The 2012 guidelines of the American Urological Association recommend an evaluation after a single positive urinalysis with mandatory upper tract evaluation in all patients, preferably with CT urography (CTU). The likelihood of detecting significant upper track abnormalities, particularly malignancies is low with CTU, while incidental extraurinary abnormalities are often found, the majority of which are not clinically significant. The workup for these incidental findings has significant financial and clinical implications. Primary care physicians, who are most apt to encounter patients with AMH, have a low rate of adherence to the AUA guidelines, possibly as a result of the broadening of criteria for AMH evaluation by the AUA, with resultant uncertainty amongst primary care physicians about the appropriate candidates for such evaluation. Selection of subgroups of patients with risk factors for GU malignancies who may benefit from a complete evaluation is essential, as opposed to evaluation of all patients classified as having AMH." /><link rel="canonical" href="https://clinicaltree.github.io/posts/evaluation-of-the-patient-with-asymptomatic-microscopic-hematuria/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/evaluation-of-the-patient-with-asymptomatic-microscopic-hematuria/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2015-07-31T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Evaluation of the Patient with Asymptomatic Microscopic Hematuria" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T03:59:08+00:00","datePublished":"2015-07-31T17:00:00+00:00","description":"Asymptomatic microscopic hematuria (AMH) is relatively common in clinical practice but the etiology remains unclear in the majority of patients; it is rarely related to genitourinary malignancies. The 2012 guidelines of the American Urological Association recommend an evaluation after a single positive urinalysis with mandatory upper tract evaluation in all patients, preferably with CT urography (CTU). The likelihood of detecting significant upper track abnormalities, particularly malignancies is low with CTU, while incidental extraurinary abnormalities are often found, the majority of which are not clinically significant. The workup for these incidental findings has significant financial and clinical implications. Primary care physicians, who are most apt to encounter patients with AMH, have a low rate of adherence to the AUA guidelines, possibly as a result of the broadening of criteria for AMH evaluation by the AUA, with resultant uncertainty amongst primary care physicians about the appropriate candidates for such evaluation. Selection of subgroups of patients with risk factors for GU malignancies who may benefit from a complete evaluation is essential, as opposed to evaluation of all patients classified as having AMH.","headline":"Evaluation of the Patient with Asymptomatic Microscopic Hematuria","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/evaluation-of-the-patient-with-asymptomatic-microscopic-hematuria/"},"url":"https://clinicaltree.github.io/posts/evaluation-of-the-patient-with-asymptomatic-microscopic-hematuria/"}</script><title>Evaluation of the Patient with Asymptomatic Microscopic Hematuria | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Evaluation of the Patient with Asymptomatic Microscopic Hematuria</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Evaluation of the Patient with Asymptomatic Microscopic Hematuria</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1438362000" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Jul 31, 2015 </em> </span> <span> Updated <em class="" data-ts="1681099148" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Justin Ziemba MD</a> </em>, <em> <a href="">Thomas J. Guzzo MD</a> </em>, <em> <a href="">Parvati Ramchani MD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="1577 words"> <em>8 min</em> read</span></div></div></div><div class="post-content"><p>Asymptomatic microscopic hematuria (AMH) is relatively common in clinical practice but the etiology remains unclear in the majority of patients; it is rarely related to genitourinary malignancies. The 2012 guidelines of the American Urological Association recommend an evaluation after a single positive urinalysis with mandatory upper tract evaluation in all patients, preferably with CT urography (CTU). The likelihood of detecting significant upper track abnormalities, particularly malignancies is low with CTU, while incidental extraurinary abnormalities are often found, the majority of which are not clinically significant. The workup for these incidental findings has significant financial and clinical implications. Primary care physicians, who are most apt to encounter patients with AMH, have a low rate of adherence to the AUA guidelines, possibly as a result of the broadening of criteria for AMH evaluation by the AUA, with resultant uncertainty amongst primary care physicians about the appropriate candidates for such evaluation. Selection of subgroups of patients with risk factors for GU malignancies who may benefit from a complete evaluation is essential, as opposed to evaluation of all patients classified as having AMH.</p><p>Hematuria has long been the subject of controversial medical inquiry. In an 1887 article on the diagnostic significance of hematuria, Robert Saundby stated that “hematuria is a symptom common to a number of pathologic conditions, which differ essentially in their seat, nature, and relationships” . Henry Wade, in a lecture to the British Medical Association in 1932, opined that the cause of hematuria “may be simple and its cure easy; but, on the other hand, it may end in the patient’s death” . Thus, even in an early era of medicine, it was recognized that hematuria was often only a symptom of a wide spectrum of urologic diseases. In the intervening years since these early publications, the ability to rapidly and easily detect hematuria, specifically microscopic hematuria, has evolved and become readily available. Therefore, we are now faced with increasing numbers of patients who undergo evaluation for asymptomatic microscopic hematuria (AMH) in efforts to detect an occult genitourinary malignancy, primarily bladder cancer, and upper tract urothelial cancer . In this review, we examine the literature regarding the evaluation of patients with AMH. The evaluation and management of patients with gross visible hematuria will not be addressed in this review.</p><h2 id="definition-and-evidence-based-guidelines"><span class="mr-2">Definition and evidence-based guidelines</span><a href="#definition-and-evidence-based-guidelines" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Microscopic hematuria is defined as the presence of more than three red blood cells (RBC) per high-power field (HPF) in a properly collected specimen of urine in the absence of contamination, infection, or other benign causes . AMH is relatively common , and its prevalence is estimated to be approximately 2.5%–13% of adult men and postmenopausal women in population-based screening studies . The etiology of AMH remains unknown in most cases (61%–77%), whereas a genitourinary malignancy is detected in only 0.43%–3.4% of patients .</p><p>The American Urological Association (AUA) developed a best practice statement in 2001 and formal evidence-based guidelines in 2012 to provide a clinical framework for the diagnosis, evaluation, and follow-up of AMH. The most recent AUA guidelines recommend an evaluation after a single positive urinalysis (hematuria on microscopy, not dipstick alone) . The evaluation includes a history, physical examination, and laboratory studies to exclude obvious benign causes . Voided urine cytology is no longer necessary, except in patients with risk factors for malignancy . Additional evaluation with a cystoscopy is required for all patients aged &gt;35 years or any patient with risk factors for malignancy such as irritative voiding symptoms, current or past tobacco use, and chemical exposures, regardless of age . Finally, imaging is deemed mandatory for all patients, preferably with multiphasic computed tomography urography (CTU) for the evaluation of the upper urinary tract .</p><h2 id="genitourinary-tract-findings-at-evaluation"><span class="mr-2">Genitourinary tract findings at evaluation</span><a href="#genitourinary-tract-findings-at-evaluation" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The etiology of AMH is rarely related to a genitourinary malignancy. In a study of 1034 patients who were evaluated with a standard regimen of urine culture, urine cytology, blood chemistry, intravenous pyelography, and cystoscopy, an etiology was identified in only 45% of cases . In these cases, a highly significant lesion, such as malignancy, requiring immediate treatment was identified in only 2.9% of patients . In the remaining cases with an etiology, 18.9% had moderately significant lesions, such as urolithiasis or glomerular disease requiring delayed treatment . Finally, 23.8% of cases had insignificant lesions, which were deemed not likely to be the cause of the hematuria . Similar rates for detection of both benign and malignant disease have been reported by other studies .</p><p>In an investigation of over 150,000 patients with more than three RBC/HPF in the urine sediment on microscopy, the rate of genitourinary malignancy was only 0.68% . The only groups which exceeded the rate for the overall cohort were men aged &gt;40 years with three or more RBC/HPF (range, 1.2%–6.11%, depending on degree of hematuria) and women aged &gt;40 years with ≥25 RBC/HPF (range, 0.87%–1.77%, depending on degree of hematuria) . Although the authors concluded these are high-risk groups, the rates of malignancy detection were still relatively low .</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="imaging-studies-in-evaluation-of-amh"><span class="mr-2">Imaging studies in evaluation of AMH</span><a href="#imaging-studies-in-evaluation-of-amh" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="extraurinary-findings-at-imaging-evaluation-for-amh"><span class="mr-2">Extraurinary findings at imaging evaluation for AMH</span><a href="#extraurinary-findings-at-imaging-evaluation-for-amh" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="adherence-to-evidence-based-guidelines"><span class="mr-2">Adherence to evidence-based guidelines</span><a href="#adherence-to-evidence-based-guidelines" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="conclusions"><span class="mr-2">Conclusions</span><a href="#conclusions" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Saundby R.: The diagnostic significance of haematuria. Br Med J 1887; 2: pp. 1320-1324.</p><li><p>2. Wade H.: A British Medical Association Lecture on THE SIGNIFICANCE OF HAEMATURIA. Br Med J 1932; 1: pp. 177-180.</p><li><p>3. Bromage S.J., Liew M.P., Moore K.C., et. al.: The economic implications of unsuspected findings from CT urography performed for haematuria. Br J Radiol 2012; 85: pp. 1303-1306.</p><li><p>4. Liu W., Mortele K.J., Silverman S.G.: Incidental extraurinary findings at MDCT urography in patients with hematuria: prevalence and impact on imaging costs. AJR Am J Roentgenol 2005; 185: pp. 1051-1056.</p><li><p>5. Song J.H., Beland M.D., Mayo-Smith W.W.: Incidental clinically important extraurinary findings at MDCT urography for hematuria evaluation: prevalence in 1209 consecutive examinations. AJR Am J Roentgenol 2012; 199: pp. 616-622.</p><li><p>6. Davis R., Jones J.S., Barocas D.A., et. al.: Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol 2012; 188: pp. 2473-2481.</p><li><p>7. Mohr D.N., Offord K.P., Owen R.A., et. al.: Asymptomatic microhematuria and urologic disease. A population-based study. JAMA 1986; 256: pp. 224-229.</p><li><p>8. Ritchie C.D., Bevan E.A., Collier S.J.: Importance of occult haematuria found at screening. Br Med J 1986; 292: pp. 681-683.</p><li><p>9. Jung H., Gleason J.M., Loo R.K., et. al.: Association of hematuria on microscopic urinalysis and risk of urinary tract cancer. J Urol 2011; 185: pp. 1698-1703.</p><li><p>10. Khadra M.H., Pickard R.S., Charlton M., et. al.: A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 2000; 163: pp. 524-527.</p><li><p>11. Loo R.K., Lieberman S.F., Slezak J.M., et. al.: Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria. Mayo Clin Proc 2013; 88: pp. 129-138.</p><li><p>12. Grossfeld G.D., Litwin M.S., Wolf J.S., et. al.: Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy—part I: definition, detection, prevalence, and etiology. Urology 2001; 57: pp. 599-603.</p><li><p>13. Grossfeld G.D., Litwin M.S., Wolf J.S., et. al.: Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy—part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up. Urology 2001; 57: pp. 604-610.</p><li><p>14. Ramchandani P, Kisler T, Francis IR. Hematuria: ACR appropriateness criteria. American College of Radiology Website. http://www.acr.org/∼/media/ACR/Documents/AppCriteria/Diagnostic/Hematuria.pdf . Published 1995. Revised 2008. Accessed May 31, 2014.</p><li><p>15. Murakami S., Igarashi T., Hara S., et. al.: Strategies for asymptomatic microscopic hematuria: a prospective study of 1,034 patients. J Urol 1990; 144: pp. 99-101.</p><li><p>16. Mariani A.J., Mariani M.C., Macchioni C., et. al.: The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol 1989; 141: pp. 350-355.</p><li><p>17. Sudakoff G.S., Dunn D.P., Guralnick M.L., et. al.: Multidetector computerized tomography urography as the primary imaging modality for detecting urinary tract neoplasms in patients with asymptomatic hematuria. J Urol 2008; 179: pp. 862-867. discussion 867</p><li><p>18. Lisanti C.J., Toffoli T.J., Stringer M.T., et. al.: CT evaluation of the upper urinary tract in adults younger than 50 years with asymptomatic microscopic hematuria: is IV contrast enhancement needed?. AJR Am J Roentgenol 2014; 203: pp. 615-619.</p><li><p>19. Bretlau T., Hansen R.H., Thomsen H.S.: CT urography and hematuria: a retrospective analysis of 771 patients undergoing CT urography over a 1-year period. Acta Radiol 2014; pii: 0284185114538250. [Epub ahead of print]</p><li><p>20. Buteau A., Seideman C.A., Svatek R.S., et. al.: What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-up. Urol Oncol 2014; 32: pp. 128-134.</p><li><p>21. Friedlander D.F., Resnick M.J., You C., et. al.: Variation in the Intensity of Hematuria Evaluation: a target for primary care quality improvement. Am J Med 2014; 127: pp. 633-640.e11.</p><li><p>22. Shinagare A.B., Silverman S.G., Gershanik E.F., et. al.: Evaluating hematuria: impact of guideline adherence on urologic cancer diagnosis. Am J Med 2014; 127: pp. 625-632.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-22/'>Volume 22</a>, <a href='/categories/issue-8/'>Issue 8</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Evaluation%20of%20the%20Patient%20with%20Asymptomatic%20Microscopic%20Hematuria%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fevaluation-of-the-patient-with-asymptomatic-microscopic-hematuria%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Evaluation%20of%20the%20Patient%20with%20Asymptomatic%20Microscopic%20Hematuria%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fevaluation-of-the-patient-with-asymptomatic-microscopic-hematuria%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fevaluation-of-the-patient-with-asymptomatic-microscopic-hematuria%2F&text=Evaluation%20of%20the%20Patient%20with%20Asymptomatic%20Microscopic%20Hematuria%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/adherence-to-thresholds/"><div class="card-body"> <em class="small" data-ts="1438362000" data-df="ll" > Jul 31, 2015 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Adherence to Thresholds</h3><div class="text-muted small"><p> Thresholds derived from quantification in imaging are increasingly used to define disease. This derivation is not an exact science. When one uses a threshold to define a disease, one does not clear...</p></div></div></a></div><div class="card"> <a href="/posts/an-overview-of-methodologies-in-detecting-overdiagnosis/"><div class="card-body"> <em class="small" data-ts="1438362000" data-df="ll" > Jul 31, 2015 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>An Overview of Methodologies in Detecting Overdiagnosis</h3><div class="text-muted small"><p> Owing to imperfect information, overdiagnosis cannot be predicted with certainty before the fact . Overdiagnosis is inferred . The fact that overdiagnosis is inferred places unique challenges on th...</p></div></div></a></div><div class="card"> <a href="/posts/analysis-of-statistical-biases-in-studies-used-to-formulate-guidelines/"><div class="card-body"> <em class="small" data-ts="1438362000" data-df="ll" > Jul 31, 2015 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Analysis of Statistical Biases in Studies Used to Formulate Guidelines</h3><div class="text-muted small"><p> Rationale and Objectives To analyze the statistical biases in the studies used to derive cardiac magnetic resonance–based major and minor criteria for the diagnosis of arrhythmogenic right ventric...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/education-in-professionalism/" class="btn btn-outline-primary" prompt="Older"><p>Education in Professionalism</p></a> <a href="/posts/intracranial-aneurysms/" class="btn btn-outline-primary" prompt="Newer"><p>Intracranial Aneurysms</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
